Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 23;11(7):1140.
doi: 10.3390/diagnostics11071140.

IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer

Toshio Fujisawa  1 , Bharat H Joshi  2 , Sho Takahashi  1 , Yusuke Takasaki  1 , Akinori Suzuki  1 , Koichi Ito  1 , Kazushige Ochiai  1 , Ko Tomishima  1 , Shigeto Ishii  1 , Raj K Puri  2 , Hiroyuki Isayama  1
Affiliations
Review

IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer

Toshio Fujisawa et al. Diagnostics (Basel). .

Abstract

IL-13Rα2 is a high-affinity binding protein for its ligand IL-13 and a cancer-testis antigen as it is expressed in the testis. IL-13Rα2 is highly expressed in various cancers, including pancreatic cancer, and consists of three domains: extracellular, transmembrane, and cytoplasmic. The extracellular domain binds to the ligand to form a biologically active complex, which initiates signaling through AP-1 and other pathways. IL-13Rα2 is also expressed in diseased cells such as fibroblasts that are involved in various inflammatory diseases, including cancer. We have reported that IL-13Rα2 is a prognostic biomarker for malignant glioma, adrenocortical cancer, and pancreatic cancer. In pancreatic cancer, a small sample of tissue could be examined for the expression of IL-13Rα2 by using the endoscopic ultrasound-fine needle aspiration technique (EUS-FNA). In addition, a peptide-based targeted approach using Pep-1L peptide could be used to study the biodistribution and whole-body cancer imaging for the screening of pancreatic cancer in suspected subjects.

Keywords: AP-1 pathway; IL-13Rα2; cancer invasion; metastasis; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The schema of mechanisms by which IL-13Rα2 promotes cancer invasion of metastasis.
Figure 2
Figure 2
The schema of mechanisms increasing expression of IL-13Rα2 in cancer cells.
See this image and copyright information in PMC

References

    1. LaPorte S.L., Juo Z.S., Vaclavikova J., Colf L.A., Qi X., Heller N.M., Keegan A.D., Garcia K.C. Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System. Cell. 2008;132:259–272. doi: 10.1016/j.cell.2007.12.030. - DOI - PMC - PubMed
    1. Suzuki A., Leland P., Joshi B.H., Puri R.K. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine. 2015;75:79–88. doi: 10.1016/j.cyto.2015.05.026. - DOI - PubMed
    1. Shimamura T., Fujisawa T., Husain S.R., Joshi B., Puri R.K. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: Role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2010;16:577–586. doi: 10.1158/1078-0432.CCR-09-2015. - DOI - PubMed
    1. Fujisawa T., Joshi B.H., Puri R.K. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int. J. Cancer. 2012;131:344–356. doi: 10.1002/ijc.26366. - DOI - PubMed
    1. Joshi B.H., Puri R.K. IL-13 receptor-α2: A novel target for cancer therapy. Immunotherapy. 2009;1:321–327. doi: 10.2217/imt.09.8. - DOI - PubMed

LinkOut - more resources